We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Natural selection

19 June 2018 By Robert Cyran

Germs are evolving immunity to existing treatments, but drug firms are reluctant to develop new ones. The costs could be monumental if they don’t. So-called patent vouchers might help – but big prizes and delinking revenue from pill sales would be cheaper ways to encourage R&D.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)